LOGIN  |  REGISTER
Viking Therapeutics

Ardent Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

December 18, 2024 | Last Trade: US$14.59 0.09 0.62

BRENTWOOD, Tenn. / Dec 18, 2024 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference being held Jan. 13-16, 2025, in San Francisco.

The management team will present at the conference beginning at 2:15 p.m. PT on Tuesday, Jan. 14, 2025. A live audio webcast of the presentation will be available at the investor relations section of the Company’s website, at ir.ardenthealth.com, and a replay will be available for 90 days using the same link.

In conjunction with the conference, the Ardent management team will be available to participate in one-on-one meetings with investors registered to attend the conference. Interested investors should contact their J.P. Morgan representative to schedule meetings.

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

Astria Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page